Biomea Fusion, they develop medicines to improve the life of the individual. The name biomea derives from the Greek word bios, meaning 鈥渓ife,鈥� and the Latin word mea, meaning 鈥渕y.鈥� They are a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is
…More a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. Leveraging their extensive expertise in covalent binding chemistry and development, they built their proprietary FUSION鈩� System platform to advance a pipeline of novel covalent therapies. Their lead product candidate, BMF-219, is an orally bioavailable, potent and selective covalent inhibitor of MENIN, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Beyond BMF-219, they are utilizing their novel platform to develop covalent treatments against other high-value oncogenic drivers of cancer. Their goal is to utilize their capabilities and platform to become a leader in developing covalent small molecules in order to maximize the depth and durability of clinical benefit when treating various cancers.
